Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05984277
Title	A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (eVOLVE-Lung02)
Acronym	eVOLVE-Lung02
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	AstraZeneca
Indications	lung non-small cell carcinoma
Therapies	Carboplatin + MEDI5752 + Pemetrexed Disodium Carboplatin + MEDI5752 + Paclitaxel Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| SVK \| POL \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG